Dr. Daniel Lebovic, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 409
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MI license 4301088178 -
Medical Oncology Physician
MI license 4301088178
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Henry Ford Health Hospital Detroit, MI
- Henry Ford Macomb Hospital Clinton Township, MI
- Henry Ford Health St John Hospital Detroit, MI
- Ascension Providence Hospital, Southfield and Novi Southfield, MI
- Henry Ford Health Warren Hospital Warren, MI
Medical groups
- Henry Ford Health St. John Hospital (348 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 409
- Services billed
- 1,403
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 527 | 207 |
| Established patient office or other outpatient visit, 20-29 minutes | 344 | 204 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 87 | 48 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 57 | 52 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 53 | 15 |
| New patient office or other outpatient visit, 45-59 minutes | 49 | 49 |
| Telephone medical discussion with physician, 5-10 minutes | 20 | 16 |
| Telephone medical discussion with physician, 11-20 minutes | 19 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Grosse Pointe Woods, MI | 215 |
| Eliquis (apixaban) Other prescribers in Grosse Pointe Woods, MI | 152 |
| Hydroxyurea Other prescribers in Grosse Pointe Woods, MI | 140 |
| Revlimid (lenalidomide) | 97 |
| Dexamethasone Other prescribers in Grosse Pointe Woods, MI | 88 |
| Lenalidomide | 77 |
| Imbruvica (ibrutinib) | 64 |
| Venclexta (venetoclax) | 54 |
| Sandostatin Lar Depot (octreotide acetate,mi-spheres) | 52 |
| Warfarin Sodium Other prescribers in Grosse Pointe Woods, MI | 47 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 20 payments worth $21,431 in total to this clinician.
| Genzyme Corporation | $13,993 |
|---|---|
| Pharmaessentia USA Corporation | $7,245 |
| GlaxoSmithKline, LLC. | $120 |
| Genentech USA, Inc. | $34.48 |
| Gilead Sciences, Inc. | $22.89 |
| Servier Pharmaceuticals LLC | $15.50 |
| Compensation for services other than consulting (speaking, faculty) | $20,889 |
|---|---|
| Food and Beverage | $336 |
| Travel and Lodging | $206 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $5,618 |
| Genzyme Corporation May 8, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $4,548 |
| Pharmaessentia USA Corporation Oct 27, 2025 | Compensation for services other than consulting (speaking, faculty) BESREMI · Oncology | $3,800 |
| Genzyme Corporation Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $3,478 |
| Pharmaessentia USA Corporation Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) BESREMI · Oncology | $1,540 |
| Pharmaessentia USA Corporation Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) BESREMI · Oncology | $1,520 |
| Pharmaessentia USA Corporation Dec 15, 2025 | Compensation for services other than consulting (speaking, faculty) BESREMI · Oncology | $385 |
| Genzyme Corporation Apr 30, 2025 | Travel and Lodging SARCLISA · Oncology · travel to Grand Rapids, MI | $206 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $8,750 in research payments for these studies, mostly to the institutions running them.
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Beigene, Ltd. · Active, not recruiting · NCT05100862
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.